Kinase inhibitor and use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9796701
APP PUB NO 20160332989A1
SERIAL NO

15108903

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
XUANZHU BIOPHARMACEUTICAL CO LTDBEIJING-TIANJIN-HEBEI COLLABORATIVE INNOVATION DEMONSTRATION PARK 203C507 769 TAIHANG STREET HIGH-TECH DISTRICT SHIJIAZHUANG HEBEI 050035 050035

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chen, Bo Shandong, CN 589 3991
Wu, Frank Shandong, CN 101 2813

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 24, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00